Peptides for chronic fatigue are not supported by good evidence. No peptide has shown benefit for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in a well-designed trial, and FDA notes there are no approved drugs for ME/CFS at all.[5] When FDA reviewed thymosin alpha-1, one of the peptides most often sold for chronic fatigue, it found no clinical studies in ME/CFS.[5] Pacing and treating the most disruptive symptoms remain the foundation of care.[2]
ME/CFS is a serious, long-term illness that can leave people housebound or bedbound, and the lack of treatments is real. This guide grades the peptides marketed for fatigue, explains what helps now, and covers the risks. For related compounds, see the longevity and immune peptides hub.
Peptides for chronic fatigue: evidence at a glance
| Peptide or approach | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Pacing and symptom-focused care | Guideline-recommended standard care | Helps prevent post-exertional crashes[2][3] | Not a drug; no drug is approved for ME/CFS[5] | — |
| Growth hormone | Small human studies | 20-patient trial: no significant quality-of-life gain at 12 weeks[6] | Approved for GH deficiency, not ME/CFS | HGH |
| SS-31 (elamipretide) | Human RCTs, other condition | Failed to improve fatigue in a genetic mitochondrial disease[7] | Approved only for Barth syndrome | SS-31 |
| Thymosin alpha-1 | No evidence, marketing only | FDA found no ME/CFS studies[5] | Not approved | Thymosin alpha-1 |
| MOTS-c | Animal or lab only | Mouse data; no human exposure data[8] | Not approved | MOTS-c |
| VIP | No evidence, marketing only | A hypothesis paper, no treatment trials[9] | Not approved for this use | VIP |
| BPC-157, KPV | No evidence, marketing only | Never tested in ME/CFS; no human data for KPV[11] | Not approved | BPC-157, KPV |
What helps ME/CFS now
The National Academies defined ME/CFS in 2015 around a few core features: a substantial drop in the ability to do pre-illness activities lasting more than six months, post-exertional malaise, unrefreshing sleep, and either cognitive problems or worsening when upright.[4] Care is built around those features.
Pacing comes first. Post-exertional malaise (PEM) is a worsening of symptoms after even minor physical or mental effort, typically 12 to 48 hours later, and it can last days or weeks. CDC advises patients to find their individual limits and plan activity and rest to stay within them, sometimes called the “energy envelope,” and warns against “push and crash” cycles.[2]
Exercise must be individual. The 2021 NICE guideline says not to offer graded exercise therapy or generalized exercise programs to people with ME/CFS, and not to present any exercise therapy as a way to make ME/CFS go away.[3]
Treat the worst symptoms. Clinicians are advised to target whatever disrupts life most, such as sleep problems, pain, dizziness on standing or thinking difficulties, using approaches tailored to the person.[2][1]
The peptides, one by one
Growth hormone
Growth hormone is a large peptide hormone. In a 1998 trial, 20 people with ME/CFS and low growth hormone peaks during sleep received growth hormone or placebo for 12 weeks. Lean mass rose and IGF-1 levels climbed, but quality of life did not improve significantly; four patients returned to work during a later open-label period, which cannot separate drug effect from other factors.[6] Growth hormone peptides such as sermorelin and ipamorelin have not been tested in ME/CFS.
Thymosin alpha-1
Thymosin alpha-1 is marketed for chronic fatigue, chronic Lyme and “long COVID.” FDA reviewed it for ME/CFS on its own initiative, found no clinical studies and concluded there was no data to support it. FDA’s review also noted that labels abroad urge caution in people with autoimmune disease.[5] Our thymosin alpha-1 vs LL-37 guide covers its trials in other conditions.
Mitochondrial peptides: SS-31 and MOTS-c
Because ME/CFS involves profound fatigue, mitochondria-targeted peptides get attention. The evidence is sobering. SS-31, also called elamipretide, was tested in 218 people with primary mitochondrial myopathy, a genetic disease where fatigue is a core symptom. After 24 weeks it did no better than placebo on fatigue or walking distance.[7] MOTS-c has only animal data; FDA found no human exposure data and no animal toxicity studies.[8] Our mitochondrial peptides research review covers both in depth.
VIP, BPC-157 and KPV
A 2006 paper proposed that autoimmunity against vasoactive neuropeptides such as VIP might drive fatigue syndromes. It was a hypothesis, not a trial, and VIP has not been tested as an ME/CFS treatment.[9] VIP is also promoted for mold-related illness, which some people confuse with ME/CFS; see our VIP and CIRS guide. BPC-157 and KPV have never been studied in ME/CFS, and FDA found no human data on KPV by any route.[11]
Why promising early results are not enough
ME/CFS research has a hard lesson about small studies. Rituximab, an immune drug, looked promising in early phase 2 trials, so Norwegian researchers ran a proper 151-patient placebo-controlled trial. Response rates were 26% with rituximab and 35% with placebo, and the drug did not help.[10] Placebo responses are large in fatigue conditions, which is why anecdotes and uncontrolled case series about peptides cannot answer whether they work.
Safety concerns
CDC notes that many people with ME/CFS are especially sensitive to medicines, may need lower-than-standard doses, and should have all medicines and supplements monitored.[13] Peptides bought online add unknowns: purity, dose and sterility are not checked, and FDA has warned that some peptides can trigger immune reactions or contain impurities.[12] A crash after an injection could be blamed on the illness, which makes harm hard to spot.
Questions for your clinician
- Have other causes of my fatigue, including sleep apnea, anemia, thyroid problems and depression, been ruled out?
- Which of my symptoms should we treat first?
- How do I find my energy limits and plan pacing?
- If I am considering a peptide, what is the evidence in ME/CFS specifically, and how would we know if it is causing harm?
The bottom line
ME/CFS has no approved drug, and no peptide has shown it helps. The best-supported care is pacing to avoid post-exertional malaise and treating the most disruptive symptoms with a clinician who knows the condition.[2][3] Peptides marketed for “energy” or “immune support” are untested in ME/CFS, and the one mitochondrial peptide tested for fatigue in a large trial failed. Related reading: peptides for long COVID, which often overlaps with ME/CFS, and our guide to animal versus human peptide studies.
This is general information, not medical advice.
